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dBuilding on the initial work by Nienaber and Dake, the
use of endovascular grafts for the treatment of type B aortic
dissections1,2 and transections3 has practically become the
standard of care over the last decade. Despite their wide-
spread use, no currently approved endovascular graft in the
United States has an indication in the product labeling for
treatment of aortic dissection or transection.
It would be of great benefit to patients and physicians
to develop scientifically valid safety and effectiveness data to
support endovascular treatment of aortic dissections and
transections as Food and Drug Administration (FDA)-
approved indications for use.4,5 Optimally, data collected
from controlled clinical studies would be available to sup-
port such new indications. However, completion of ran-
domized trials, or enrollment of concurrent surgical con-
trol populations, is likely not feasible for aortic dissections
or transactions due to their relatively low incidence.6,7 In
addition, randomization is not feasible given a lack of
clinical equipoise with open surgical repair. Because of
these challenges in conducting controlled clinical studies,
the FDA has become open to considering single-arm stud-
ies for endovascular treatment of aortic dissections and
transections.
ACUTE COMPLICATED TYPE B AORTIC
DISSECTIONS
Applicability of the device master file. In the ab-
sence of an active control arm, interpretation of study data
can be challenging. The establishment of a relevant primary
response variable, with a prospectively defined definition of
success, improves the integrity of a single-arm study. For
dissection studies, success may be based on a 30-day mor-
tality performance goal, because operative mortality is an
objective measure of the safety of the treatment. Data from
the device master file (MAF) of studies of endovascular
grafts used to treat acute complicated type B aortic dissec-
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urgery (SVS), can be used to establish an appropriate goal.
he data in the MAF were prospectively collected under
ve independent investigator-sponsored investigational de-
ice exemption (IDE) studies.
As is often the case with investigator-sponsored IDEs,
hese studies differed frommanufacturer-sponsored studies
ecause they were not designed to support marketing ap-
lications or labeling changes for approved devices. These
DEs provided opportunities for the investigators to study
he devices under conditions different from those in the
ore narrowly defined manufacturer-sponsored studies.8
n the SVS MAF, the investigator-sponsored IDEs were
ingle-center studies that used unique protocols and several
ifferent endovascular graft designs. A common set of
efinitions was developed and applied retrospectively to
llow for the pooling of the data from the individual
tudies. Analysis of these pooled data demonstrated a 30-
ay mortality rate of 11%  7% ( 95% confidence limit)
ssociated with the use of endovascular grafts for treatment
f complicated acute type B aortic dissections.
Limitations are inherent in the design of any single-arm
tudy because the treatment group may differ in its baseline
linical characteristics compared with the control. Use of
he SVS MAF reduces the bias associated with use of a
erformance goal because the MAF contains prospectively
ollected, patient-level data for a well-defined patient pop-
lation, even though definitions were applied retrospec-
ively. The population is limited to patients with acute type
aortic dissections with malperfusion or rupture, exclud-
ng patients with more controversial and less specific indi-
ations for treatment, such as dissection in the presence of
ncontrolled hypertension. Limiting the definition of
complicated” to patients with malperfusion or rupture
nables manufacturers to define study enrollment criteria
recisely and facilitates comparison of the populations and
utcomes by using common definitions.
The expected 30-day mortality rate from the MAF can
e used as the foundation for establishing an appropriate
ortality-based performance goal for an individual study, but
ata from previous studies of the device and endovascular and
pen surgical literature are needed to set a reasonable expec-
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mortality rate for an individual device study could be between
4% and 18% according to theMAFdata, the performance goal
should also take into account factors such as variability in
outcomes due to differences in center experience, the aggres-
sive nature of the disease,9,10 and the fact that open surgical
repair may be associated with a higher rate of operative mor-
tality11,12 compared with endovascular repair.
TheMAF provides other information that will be useful
when interpreting the results of the clinical studies. For
example, the MAF includes information on baseline vari-
ables to allow for comparison of the study population to the
MAF population. It also provides comparative information
for major adverse events and longer-term (90-day and
1-year) mortality data.
Data from clinical studies using theMAF to support the
definition of a performance goal may be useful in the design
of other studies needed to evaluate the safety and effective-
ness of endovascular grafts to treat acute and chronic dis-
sections or may provide useful information to physicians to
identify individual patients that may benefit from endovas-
cular repair. The performance goal for future studies may be
updated and further refined as the body of available clinical
evidence becomes larger. For example, because the effects of
the malperfusion or rupture may linger, we may find that it is
more appropriate to use a 90-day end point rather than the
more commonly applied definition for operative mortality of
30 days once additional data on endovascular treatment of
acute dissections become available.
Challenges in evaluating dissection treatments. Al-
though the MAF is superior to the use of literature to
establish a primary safety performance goal, there are chal-
lenges in evaluating endovascular grafts for the treatment of
dissections that are not addressed through the use of the
MAF. Using a narrow definition for “complicated dissec-
tion” improves the scientific focus of the studies but does
not provide adequate information to determine, on a pop-
ulation level, when an intervention is needed in a nonrup-
ture or malperfusion setting. If studies attempt to address
the question of whether patients with other indications,
such as intractable pain, may benefit from this therapy, it
may not be appropriate to use the MAF to establish a
performance goal. Clearly, studies designed around use of
this MAF will not fully address the treatment of chronic
dissections because the clinical need for intervention is not
always clear, the population is less homogeneous compared
the acute population described in the MAF, and device
effects may be different depending on the ability of the
endovascular graft to remodel the true lumen.
An additional challenge in evaluating a dissection treat-
ment is in defining effectiveness. Not unlike the early days
of endovascular graft treatment of aneurysms, the signifi-
cance of different types of endoleak is unclear. Studies of
endovascular grafts used to treat dissections should capture
extensive information on false lumen behavior and corre-
late observations with clinical outcomes. Definitions for
various types of flow into the false lumen should be estab-
lished. As the body of clinical evidence becomes larger, it sill likely be possible to establish a separate performance
oal for effectiveness. Until then, the primary evaluation of
afety and effectiveness can be combined, based on early
ortality rates, with all available evidence considered when
valuating the risks and benefits of the devices.
Ultimately, it would be preferred to develop robust
bjective performance criteria (OPCs) for endovascular
raft studies. Establishment of OPCs generally requires
elatively mature device technology and the availability of
igh-quality clinical evidence. Data collected from studies
hat use the MAF ideally will be used collectively to estab-
ish appropriate OPCs. The MAF could provide a mecha-
ism for capturing the data in a centralized location, under
“living registry.”
ORTIC TRANSECTIONS
The SVS has also submitted to the FDA, under a
eparate master file, data from the investigator-sponsored
tudies describing patients treated for transections and their
utcomes that will similarly help in the interpretation of
ndovascular graft transection study results. However,
iven the additional challenges with designing robust stud-
es of the treatment of transections, the use of this MAFwill
e different than for the dissection MAF.
As with the treatment of dissections, the purpose of
reating aortic transections is to avoid death. Unlike for
issections, the predominant cause of death for patients
ith transections is not often aorta-related owing to their
ssociated multiple and severe injuries. Even the risk of
ortic treatment-related death is associated with the severity
f concomitant injuries. Mortality is not an unambiguous
easure of success for endovascular repair of transections.
When considering how to evaluate the safety and effec-
iveness of an endovascular graft for treatment of aortic
ransections, it is important to consider that the safety and
ffectiveness of the system would have likely been previ-
usly demonstrated for treatment of aortic aneurysms.
dentifying unique concerns with treatment of transections
hould take into account the potential anatomic differences
n the patients with transections compared with aneurysms
nd the types of reported events associated with treatment
f transections. Because patients with transections are likely
o be younger and without significantly diseased vessels,
hallenges associated with endovascular treatment are often
ue to their smaller and more angulated aortas at the
mplantation site. Reported events associated with the
reatment of transections tend to be related to these differ-
nces and manifest early. Building on the foundation of the
afety and effectiveness of the device for treatment of aneu-
ysms and descriptively demonstrating a reasonable early
afety and effectiveness profile for treatment of transections
hould provide adequate information to support an indica-
ion for treatment of transections. The information in the
ransection MAF may be used when considering whether
tudy outcomes are as anticipated.
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Balancing the desire for definitive clinical evidence with
the reality of conducting clinical studies for uncommon con-
ditions is an evolutionary process. The availability of theMAF
for acute complicated type B aortic dissections allows for a
more mature study design and data analysis than would be
possible if relying on literature-based historical information.
Minimizing the inherent bias in conducting relatively small,
single-arm studies through use of the MAF and consistent
definitions will enable the collection of additional clinical
evidence that can be used to improve the robustness of future
studies. Extrapolation of this evidence to other types of dis-
sections and indications for intervention will need to be con-
sidered when the data become available, in addition to using
these data to help in defining additional studies.
Use of the transection MAF will similarly aid in the
interpretation of study data, although the nonuniformity of
the patient population with aortic transections further lim-
its the ability to design robust clinical studies. As additional
transection studies are completed, it may possible to better
define expected outcomes.
Collaboration of all stakeholders, including the clinical
community, medical device manufacturers and regulatory
agencies interested in addressing areas of controversy in
treating dissections and transections will facilitate the
achievement of this common goal. To this end, use of the
MAFs provide not only enhanced starting points, but may
also be used as living registries to prospectively capture
additional clinical evidence. Continued collaboration with
FDA during the early planning stages of study design and
continued collection and submission of dissection data to
FDA is crucial in advancing the evaluation of dissection and
transection treatments.EFERENCES
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